共 50 条
- [41] Phase I/II trial of primary chemotherapy with nonpegylated liposomal doxorubicin, paclitaxel, and lapatinib in patients with HER2-positive, early-stage breast cancerJOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Kuemmel, SherkoAktas, BahriyeKrocker, JuttaElling, DirkLantzsch, TilmannBischoff, JoachimFersis, NikosBoehme, MichaelBelau, AntjeLampe, DieterSchmid, Peter
- [43] Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trialCANCER RESEARCH, 2021, 81 (04)Holmes, Frankie AnnMoy, BeverlyDelaloge, SuzetteChia, StephenEjlertsen, BentMansi, JanineIwata, HirojiGnant, MichaelBuyse, MarkBarrios, CarlosSilovski, TajanaSeparovic, RobertBashford, AnnaGuerrero-Zotano, AngelDenduluri, NeelimaPatt, DebraGokmen, ErhanGore, IraSmith, JohnBryce, RichardXu, FengWong, AlvinMartin, MiguelChan, Arlene
- [44] Phase 1/2 dose-escalation and expansion study investigating SAR439859+/- palbociclib in postmenopausal women with estrogen receptor-positive (ER+)/HER2-metastatic breast cancer.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Bardia, AdityaLinden, Hannah M.Ulaner, Gary A.Chandarlapaty, SaratGosselin, AliceCelanovic, MarinaCampone, Mario
- [45] A Phase.b Study of D-0502 as Monotherapy for Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer: Results from the Dose-Expansion StageCANCER RESEARCH, 2024, 84 (09)Wang, JiayuSun, TaoZhang, QingyuanShi, YanxiaWang, XuChen, YidingOuyang, QuchangLi, KunyanBupathi, ManojkumarEdenfield, W. JefferySilber, Andrea L. M.Zong, HongHamilton, ErikaJuric, DejanLathrop, KateZhang, YihongStazzone, KathrynShi, ZheWang, YaolinZhang, LingXu, Binghe
- [46] A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy resultsANNALS OF ONCOLOGY, 2024, 35 (08) : 707 - 717Hamilton, E.Oliveira, M.Turner, N.Garcia-Corbacho, J.Hernando, C.Ciruelos, E. M.Kabos, P.Ruiz-Borrego, M.Armstrong, A.Patel, M. R.Vaklavas, C.Twelves, C.Boni, V.Incorvati, J.Brier, T.Gibbons, L.Klinowska, T.Lindemann, J. P. O.Morrow, C. J.Sykes, A.Baird, R. D.
- [47] First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric CancerMOLECULAR CANCER THERAPEUTICS, 2021, 20 (08) : 1442 - 1453Pegram, Mark D.Hamilton, Erika P.Tan, Antoinette R.Storniolo, Anna MariaBalic, KemalRosenbaum, Anton, ILiang, MeinaHe, PengMarshall, ShannonScheuber, AnitaDas, MayukhPatel, Manish R.
- [48] Phase II trial of rifaximin in patients with early-stage HER2 positive breast cancer with gastrointestinal toxicities related to pertuzumab-based therapy.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Chumsri, SaranyaHarlos, ElizabethLiu, HeshanStark, Emily R.Muller, Aixa Elena SoyanoWeidner, MorganCornell, LaurenRoseberry, Beverly J.Advani, Pooja PremErnst, BrendaRao, RohitSideras, KostandinosMoreno-Aspitia, AlvaroVazquez-Roque, Maria I.
- [49] NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib (N) in women with metastatic HER2+breast cancer (MBC)JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Abraham, JamePuhalla, ShannonSikov, William M.Montero, Alberto J.Salkeni, Mohamad AdhamRazaq, WajeehaBeumer, Jan HendrikKiesel, BrianBuyse, Marc E.Adamson, Laura M.Srinivasan, AshokPogue-Geile, Katherine L.Allegra, Carmen JosephJacobs, Samuel A.
- [50] Final findings from the CONTROL trial of diarrheal prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+early-stage breast cancerCANCER RESEARCH, 2022, 82 (04)Chan, ArleneRuiz-Borrego, ManuelMarx, GavinBrufsky, AdamChien, JoThirlwell, MichaelTrudeau, MaureenBose, RonGarcia-Saenz, Jose A.Egle, DanielPistilli, BarbaraWassermann, JohannaCheong, Kerry A.Singer, Christian F.Hunt, DanielForuzan, NavidMcCulloch, LeanneBarcenas, Carlos H.